

Oncimmune

07:04 11 Jun 2019

Oncimmune gets lift from Scottish lung cancer study success

- Oncimmune's EarlyCDT test met its primary endpoint in a substantial study of lung cancer patients undertaken by the NHS
- The primary endpoint was the difference, at 24 months after randomisation, between the rates of patients with stage III, IV or unclassified lung cancer
- The company already has European CE mark approval for the EarlyCDT- Lung test and has 18 global agreements in place with a total minimum of £33.5m sales
- In May, the company also announced the start of a major trial in China to test for early-stage lung cancer
- At 86.5p share, Oncimmune is valued at £58m

What the company does:

Oncimmune PLC (LON:ONC) is a specialist in the field of immunodiagnostics.

Specifically, its technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis.

Founded in 2002, it launched its platform technology in 2009, followed by its first commercial tests - EarlyCDT-Lung and EarlyCDT-Liver.

To date, over 155,000 Oncimmune tests have been performed worldwide.

EarlyCDT-Lung was used in the largest-ever trial for the early detection of lung cancer using biomarkers - the National Health Service's Early Cancer Detection Test-Lung Cancer Scotland (ECLS) study of 12,210 high-risk smokers in Scotland.

Oncimmune also develops precision medicine and patient tools that allow doctors to place people being treated for cancer and autoimmune diseases into certain patient sub-groups, a process called stratification.

Scottish NHS study success:

A total of 12,210 Scots were monitored for two years as part of the ECLS initiative in what is believed to be the largest randomised controlled assessment of its kind.

Sponsored by the University of Dundee and NHS Tayside and co-funded by the Chief Scientist Office, the study, to use the scientific parlance, hit its primary end-point.

Specifically, monitoring recruits reduced the incidence of people with late-stage lung cancer, or "unclassified presentation at diagnosis", compared to standard clinical practice.


What the boss says - Adam Hill, chief executive:

"Lung is the largest market in terms of unmet need in cancer diagnosis today.

Price: 89p

Market Cap: £5850640000M

1 Year Share Price Graph



August 2018 February 2019 August 2019

Share Information

Code: ONC

Listing: AIM

52 week High Low
138.50p 77.00p

Sector: Pharma & Biotech

Website: oncimmune.com

Company Synopsis:

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated.

action@proactiveinvestors.com

"Of those detected, 75-80% are in the late stages where treatment options are limited and survival rates relatively poor.

"One way to tackle this is to detect it earlier in stages one or two, which gives better treatment options."

Video

Inflexion Points

Last October, Oncimmune outlined a three-year strategy that will see the company focus on its core business of cancer early detection while looking for value- and revenue-enhancing partnerships and acquisitions.

In March it delivered on the acquisitions portion when it bought Protagen Diagnostics for up to £4.11 mln-worth of shares. The deal will accelerate Oncimmune's biomarker discovery process and grow its development library to over 8,000 proteins.

Preparations are now underway in Scotland to conduct "a phased population-based" evaluation using EarlyCDT-Lung that would recruit 200,000 people.

The Oncimmune blood test would be supplied on "negotiated commercial terms", the company said.

A submission of the full ECLS study findings will be made to an unnamed, peer-reviewed medical publication sometime in the next quarter.

And a late-breaking abstract is being prepared for the International Association for the Study of Lung Cancer World Conference on Lung Cancer on 7-10 September 2019 - the world's largest lung cancer gathering.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.